Results 201 to 210 of about 94,612 (306)
Toward Clinically Feasible Assessment of Muscle Mass: Validation of a Seated Bioelectrical Impedance Device Against Dual-Energy X-Ray Absorptiometry (DXA) in Older Adults. [PDF]
Piche E +4 more
europepmc +1 more source
ABSTRACT Objective Age‐related loss of lean mass is a hallmark of sarcopenia and a contributor to functional decline and morbidity in ageing populations. This study aimed to identify long‐term determinants of lean mass during ageing. Methods Data from 3033 participants (ages 20–96 years; 49% women) in the Geelong Osteoporosis Study were analysed using ...
Aminu Suleiman +6 more
wiley +1 more source
Distinct Cortical Microstructure in Postmenopausal Women with Distal Radius and Proximal Humerus Fractures. [PDF]
Bartosik M +6 more
europepmc +1 more source
Musculoskeletal health among adults with cerebral palsy: A systematic review
Abstract Aim To describe the burden of, and investigate prognostic factors for, osteoarthritis, osteopenia and/or osteoporosis, spondylosis, and fracture, and to investigate the effectiveness of protocols for monitoring musculoskeletal disorders and interventions for managing osteoarthritis in adults with cerebral palsy (CP).
Jennifer M. Ryan +11 more
wiley +1 more source
This systematic review reports on quantitative measures of intrinsic capacity domains of the WHO Healthy Ageing model for adults with CP. Reports from 102 studies showed reduced locomotor, vitality andn possibly cognitive intrinsic capacity reserves for adults aged 30–45 years.
Woroud Alzaher +4 more
wiley +1 more source
Monitoring nutritional consequences of obesity treatment on long-term health of women and their offspring: protocol of a multicentre prospective cohort study. [PDF]
Schipper RM +6 more
europepmc +1 more source
ABSTRACT Aims To assess the effect of semaglutide on body composition and physical function. Materials and Methods The phase 3b STEP UP trial randomised adults with body mass index ≥ 30 kg/m2 to once‐weekly subcutaneous semaglutide 7.2 mg, semaglutide 2.4 mg or placebo for 72 weeks.
Jøran Hjelmesæth +8 more
wiley +1 more source

